Semaglutide Slashes Eosinophil Counts in Real-World Study of 371 Adults
A new real-world study finds semaglutide significantly reduces blood eosinophil levels, with the strongest effect in non-obese individuals.
Summary
A retrospective study of 371 adults prescribed semaglutide at a Shanghai hospital found that the GLP-1 receptor agonist significantly reduced blood eosinophil counts — key inflammatory cells implicated in asthma and allergic disease. Eosinophil counts fell from a median of 160 to 110 per microliter, and the proportion of participants with counts under the clinically relevant 150/µL threshold rose from 44% to 66%. The effect occurred regardless of starting eosinophil level, but was more pronounced in non-obese patients. Higher baseline eosinophil count was the only independent predictor of how much reduction occurred. These findings suggest semaglutide may have anti-inflammatory benefits beyond blood sugar and weight control.
Detailed Summary
GLP-1 receptor agonists like semaglutide have transformed diabetes and obesity care, but researchers are increasingly asking whether their benefits extend into immunology and respiratory medicine. Elevated blood eosinophils are a hallmark of eosinophilic asthma and other allergic conditions, driving airway inflammation and disease severity. If semaglutide can meaningfully lower these counts, it could represent a significant secondary benefit for a large population of patients.
This retrospective, single-center study enrolled 371 adults newly prescribed semaglutide at Shanghai General Hospital's outpatient clinic. Researchers compared complete blood counts and lipid profiles before and after treatment, stratifying participants by baseline eosinophil count (above or below 150/µL) and BMI (above or below 28 kg/m²).
The results were striking. Median blood eosinophil counts fell from 160 to 110 per microliter — a statistically significant drop — and eosinophil percentage declined from 2.20% to 1.60%. The share of patients below the 150/µL clinical threshold increased from 44% to nearly 66%. Importantly, reductions occurred in both the high and low baseline eosinophil groups. Non-obese individuals (BMI below 28) experienced a greater percentage reduction than obese individuals (−31.6% vs. −21.0%). Multiple regression confirmed that only baseline eosinophil count independently predicted the magnitude of reduction.
These findings carry real clinical weight. Patients with eosinophilic asthma, chronic rhinosinusitis, or eosinophilic esophagitis who require metabolic management may derive an added anti-inflammatory benefit from semaglutide. The more pronounced effect in non-obese patients is counterintuitive and warrants mechanistic investigation.
Caveats are significant. The study is retrospective, single-center, and conducted in a Chinese population, limiting generalizability. Causation cannot be firmly established, and the full paper — including treatment duration and dosing details — was not available for review, as this summary is based on the abstract only.
Key Findings
- Semaglutide reduced median blood eosinophil counts from 160 to 110/µL across 371 adults (P < 0.001).
- The share of patients with eosinophil counts below 150/µL jumped from 44% to 66% after treatment.
- Non-obese adults saw greater eosinophil reduction than obese adults (−31.6% vs. −21.0%).
- Higher baseline eosinophil count was the only independent predictor of treatment-induced reduction.
- Eosinophil reductions occurred regardless of whether baseline levels were high or low.
Methodology
Retrospective, single-center study at Shanghai General Hospital enrolling 371 adults first prescribed semaglutide in an outpatient clinic. Blood counts and lipid profiles were collected from electronic medical records before and after treatment. Multiple linear regression was used to identify independent predictors of eosinophil reduction.
Study Limitations
The study is retrospective and single-center, limiting causal inference and generalizability beyond the Chinese patient population studied. Treatment duration, dosing details, and comorbidity data are not reported in the abstract. This summary is based on the abstract only, as the full paper was not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: